Moxibustion: asthma and rhinitis

Short answer: reviews report some favourable outcomes for specific moxibustion methods and combinations in asthma and allergic rhinitis, with important limits in evidence quality ^[1][2]. Smoke intolerance and coughing are documented in moxibustion safety sources ^[3][4]. Mugwort pollen is a recognised allergen, but pollen sensitisation does not by itself prove an individual reaction to a processed moxa stick or its smoke ^[5]. A respiratory condition makes exposure and clinical-care context central to the decision.

People with asthma should not change inhaler or medication use based on this page. Evidence summary only.

Asthma

The 2024 review includes both add-on and active comparisons. In the add-on comparison, both groups received anti-asthma medicine; in the active comparison, a moxa intervention was compared with medicine. Those are different questions. The abstract reports an increase in IgE in one add-on analysis; that direction should not be paraphrased as “IgE improved” without an explanation of the measure and its clinical meaning. It also found no effect on children’s quality of life in the add-on comparison and inconsistent immune-cell findings ^[1]. A review conclusion using the phrase “good safety” reflects adverse events reported in its included trials, not a safety guarantee for someone with asthma exposed to smoke in a different room.

Allergic rhinitis (hay fever)

A positive ranking can hide an imprecise comparison

The 2023 rhinitis network placed heat-sensitive moxa first on a composite effectiveness measure, but its reported interval for that comparison stretches from 1.86 to 1,360.2. Such width means the magnitude is highly uncertain. Its ranking cannot prove that a particular retail low-smoke stick is best, especially when the network compares nine clinical methods ^[7]. The 2026 adult network combined needle methods, acupoint embedding and different forms of moxa; top performers varied between nasal symptoms and quality-of-life measures ^[8]. The reader needs the exact symptom, comparator and treatment combination, not a single “best moxa” label.

The smoke and pollen paradox

• Moxa smoke contains particles and oily aerosols ^[10][11]. Coughing and smoke intolerance are reported ^[4][3]. The filtration paper’s allergic-rhinitis experiment was conducted in mice; it supports a mechanistic concern, not a measured human asthma-attack probability ^[11].
• Mugwort pollen is an allergen with cross-reactivity in people sensitised to particular pollens ^[5][12]. Pollen exposure, contact with processed dried material and inhalation of combustion products are different exposure routes. One cannot infer a personal smoke allergy from a pollen test alone or assume that a low-smoke label eliminates allergen concern.
• Practical consequence: asthma medicines and clinical guidance remain primary. Anyone considering a session can discuss smoke, room ventilation, heat method and personal triggers with a clinician. A “smokeless” or “low-smoke” label is not an air-quality measurement for the exact product and room ^[13][14].

What does an add-on asthma comparison tell us?

The 2024 review searched seven databases through June 23, 2024 and included 37 trials with 2,879 participants. It distinguished moxibustion added to anti-asthma medicines from active comparisons of moxibustion against medicines ^[1]. The first asks about an adjunct while the drug treatment remains present; the second asks a different comparison. Neither should be silently rewritten as instructions to stop prescribed care.

The review reported favourable add-on findings for several response, lung-function and control outcomes, but no effect on children’s quality of life. Its immune-cell results varied between the add-on and active comparisons, and certainty ranged from moderate to very low ^[1]. A complete summary retains the outcome that did not improve as well as the favourable ones. The total trial count is not necessarily the number contributing to each particular outcome.

Why is the IgE wording important?

The abstract describes greater increases in IgE in one add-on comparison ^[1]. This page preserves that reported direction rather than translating it into “IgE decreased” or using the broad word “improved” as though the clinical interpretation were obvious. A biomarker’s direction, its role in the analysis and its clinical meaning need the actual paper and context.

That is a practical source-reading safeguard. A positive conclusion at the end of an abstract does not make every measured indicator a favourable clinical effect. A symptom, lung-function measure, immune-cell proportion and quality-of-life score should remain separate results, with their comparisons and certainty.

Why are the rhinitis comparisons not all indirect-moxa-alone trials?

The 2022 indirect-moxibustion review included 21 trials and 1,549 participants. Its abstract separates five studies using indirect moxa alone from 16 using it with other active interventions ^[2]. A pooled result should therefore not be presented as 21 isolated tests of one moxa technique. The exact comparison and additional treatments matter.

The review reported favourable findings on several symptom and response measures, while finding no clear advantage on the visual-analogue score or serum IgE. It described the overall outcome evidence as low and discussed small samples and methodological limits ^[2]. These differences show why an overall “works for hay fever” statement is less informative than an endpoint-specific description.

What do network rankings add, and what do they leave open?

The 2026 network analysis included 56 studies and 4,859 participants, comparing multiple acupuncture-related methods. Different combinations ranked highly for clinical response, nasal symptoms, non-nasal symptoms and rhinitis-related quality of life; the leading short-term and longer-term categories also differed ^[8]. A combined hand-acupuncture-and-moxa category should retain the needle component in its name.

The earlier 2023 moxa network’s very wide reported interval is another reason to keep ranks beside uncertainty ^[7]. Being placed first does not establish a precise effect size or identify the best retail stick. A network category can cover a clinical procedure rather than a single standardized product. It may also rely on indirect comparisons rather than a direct trial between every pair of options.

How should smoke, pollen and reported adverse events be kept separate?

The asthma review described reported moxa-related adverse events as mild ^[1]. That finding is confined to what its included trials reported; it is not a guarantee that a new participant, product or room will produce only mild effects. The safety sources elsewhere in this guide include coughing and smoke intolerance ^[3][4]. Retain both evidence scopes rather than allowing one to erase the other.

Mugwort pollen sensitisation is a different exposure question from contact with processed material or inhalation of combustion products ^[5]. A pollen test alone cannot establish an individual response to a particular burning product. Equally, the absence of a visible plume or the word “smokeless” cannot establish absence of irritating gases or determine the air conditions in a specific treatment room.

What information is useful for a clinical discussion?

Identify the respiratory diagnosis, current care, proposed heat or moxa method, product ingredients and the room or exposure being considered. Bring the paper’s exact comparator and outcome if a research claim is part of the question. A clinical trial of a defined add-on procedure is not an emissions test of a buyer’s chosen sample.

For a product evaluation, keep any smoke or gas report with its method, article and conditions. For treatment decisions, the responsible clinician needs the individual clinical context. The smoke and air page and allergy page discuss these different records without treating a product label as a personal safety assessment.

Related pages

• Mugwort allergy
• Moxa smoke chemistry

Moxa Sourcing

Need a sourcing brief?

Moxa Sourcing helps brands and clinics compare product formats and samples, plan private-label packaging and coordinate export handoff. Start with your market, quantity and packaging goals.

What details help us start?

Share the format, market, quantity, packaging, destination and expected timing.

Buyer guideSend a buying brief